Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Consolidation Approach Extends PFS in Multiple Myeloma

April 20th 2017

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival compared with RVD alone in patients with multiple myeloma.

Guideline Emphasizes Emotional, Physical Needs of Myeloma Patients

April 18th 2017

There is no comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of myeloma patients. The UK Myeloma Forum and the British Society for Haematology set out to address this need and published such a guideline in a recent issue of the British Journal of Hematology.

Dr. Thompson on Challenges Facing the Field of Multiple Myeloma

April 12th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses challenges facing the field of multiple myeloma.

Beyond Myeloma: New Roles for IMiDs

April 10th 2017

The past several decades have witnessed a dramatic improvement in the treatment of patients with multiple myeloma, the second most common type of hematologic malignancy. A better understanding of the biology of this disease and the introduction of a wealth of novel drug classes has more than doubled median survival times.

FDA Approval Sought for Denosumab in Myeloma

April 6th 2017

A supplemental biologics license application has been submitted to the FDA for the use of denosumab for the prevention of skeletal-related events in patients with multiple myeloma.

Dr. Landgren on Managing Toxicities of Multiple Myeloma Treatment

April 3rd 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.

Dr. Smith Discusses CAR T Cells in Multiple Myeloma

March 28th 2017

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

March 27th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple Myeloma

March 24th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

Dr. Usmani on Mechanisms and Response Rates With Daratumumab in Myeloma

March 24th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the mechanisms of daratumumab (Darzalex) as well as the reported response rates in combination with other agents in multiple myeloma.

Dr. Thompson on the Future of Treatment in Multiple Myeloma

March 24th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.

Dr. Landgren on Using Daratumumab for Patients With Multiple Myeloma

March 23rd 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses using daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Dr. Lonial Discusses Recent Updates in Multiple Myeloma

March 9th 2017

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Lonial Discusses Dramatic Progress in Multiple Myeloma

March 8th 2017

Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.

Novel Study of Next-Generation BCMA-Targeted CAR-Modified T Cells for Multiple Myeloma Opens at MSK

March 6th 2017

Ola Landgren, MD, PhD, discusses a new clinical trial at Memorial Sloan Kettering examining a novel myeloma-directed CAR T-cell therapy developed by researchers at the cancer center.

Denosumab Effective in Delaying SREs in Myeloma

March 6th 2017

Denosumab (Xgeva) demonstrated noninferiority to zoledronic acid (Zometa) at delaying the time to the first skeletal-related event in patients with multiple myeloma, according to the full results of the phase III 482 study presented at the 16th International Myeloma Workshop in New Delhi.

Dr. Lonial on Advancements in the Treatment of Myeloma

March 2nd 2017

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer at Winship Cancer Institute of Emory University, discusses recent advancements in the field of multiple myeloma.

Carfilzomib Improves Survival in Relapsed Multiple Myeloma

March 1st 2017

Carfilzomib (Kyprolis) plus dexamethasone improved overall survival by 21% versus dexamethasone plus bortezomib (Velcade) in patients with relapsed or refractory multiple myeloma, according to findings from the phase III ENDEAVOR trial.

Outcomes Have Improved Over Time in Myeloma Patients Relapsing Early After ASCT

February 25th 2017

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

Carfilzomib Maintenance Improves Response Following Transplant in Relapsed Multiple Myeloma

February 25th 2017

According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.